Osteoarthritis Drugs Market

Osteoarthritis Drugs Market (Drug Class: Corticosteroids, NSAIDs & Others, and Viscosupplementation Agents; and Route of Administration: Oral, Parenteral, and Topical) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Osteoarthritis Drugs Market Outlook 2031

  • The industry was valued at US$ 8.6 Bn in 2022
  • It is expected to grow at a CAGR of 8.5% from 2023 to 2031 and reach US$ 17.7 Bn by the end of 2031

Analyst Viewpoint

Growth in incidence of osteoarthritis and rise in geriatric population are fueling the osteoarthritis drugs market development. Advancements in medical research and pharmaceutical development are likely to offer lucrative opportunities to vendors in the osteoarthritis drugs industry landscape.

Companies in the market are exploring ways to devise asymptomatic osteoarthritis drugs, which would provide a preventive care in the long run. They are developing and commercializing injectable resiniferatoxin for osteoarthritis of the knee.

The ongoing efforts within the pharmaceutical sector to address the unmet medical needs of osteoarthritis patients and improve their quality of life are driving the osteoarthritis drugs market trajectory.

Market Introduction

Osteoarthritis, better known as degenerative joint disease, majorly impacts the neck, knees, hips, lower back, and small joints of fingers. The disease progresses gradually, which results in moderate to severe pain in the body parts mentioned above, and low quality of life, especially in the population subject to low physical activity or the one with higher body mass index (BMI).

Oral, topical, and parenteral pain medications are broadly used for managing pain associated with osteoarthritis. Research states that oral analgesics, topical agents, intra-articular agents, and nutraceuticals offer 30% reduction in pain due to osteoarthritis.

The ongoing trend is that of devising personalized medicines for osteoarthritis. Essential features about biomarkers that would have clinical relevance regarding the personalized approach to therapy include acceptable levels of specificity and sensitivity, ease of measurement, and test methods interpretable by the clinicians.

This concept of personalization of medicines is expected to be one of the factors driving the osteoarthritis drugs market demand.Using prescription NSAIDs and OTC causes side effects such as adverse cardiovascular events.

Cyclooxygenase (COX)-2 selective NSAIDs (coxibs) as well as non-selective NSAIDs increase the risk of cardiovascular diseases in patients. This factor is likely to restrain the osteoarthritis drugs market opportunities during the forecast period.

Attribute Detail
Market Drivers
  • Growth in Incidence of Osteoarthritis
  • Rise in Geriatric Population

Growth in Incidence of Osteoarthritis Fueling Osteoarthritis Drugs Market Value

A noticeable increase in the obese population, and, in turn, the population affected by osteoarthritis, is expected to drive the osteoarthritis pharmaceuticals market size during the forecast period.

The modern-day sedentary lifestyle has raised the obesity quotient (OQ) globally. This, in turn, results in exerting excessive pressure on hips and knees, which is likely to affect cushion joints for breaking down faster.

CDC, in May 2022, released a report stating that the prevalence of obesity was 39.8% amongst those aged between 20 and 39, 41.5$ amongst those aged 60 and above, and 44.3% amongst adults aged between 40 and 59. It further states that The U.S. witnessed increase in incidence of obesity to 41.9% from 30.5% between March 2019 and March 2020.

Rise in Geriatric Population Augmenting Market Progress

The older population is more prone to osteoarthritis as aging alterations in musculoskeletal system raise propensity to osteoarthritis. Additionally, joints affected are generally related to other osteoarthritis risk factors such as genetics, obesity, joint injury.

As per the data published by the UN in 2022, 16% of the global population will cross 65 by the year 2050. Moreover, PubMed Central had published an article in September 2022 stating that osteoarthritis is the prime cause of disability amongst the geriatric population. Need to treat this sizable population is driving the osteoarthritis drugs market growth.

Osteoarthritis Drugs Market Regional Insights

Attribute Detail
Leading Region North America

North America held the largest osteoarthritis drugs market share in 2022. The region is expected to continue with its dominance even during the forecast period. Rise in prevalence of osteoarthritis is fueling the market dynamics of the region.

As per the National Public health Agenda report for Osteoarthritis 2020, osteoarthritis affects nearly 32.5 million people in the U.S. As per data published by Arthritis Society Canada in September 2021, over 4 million Canadians are suffering from osteoarthritis.

Europe’s osteoarthritis drugs industry growth can be ascribed to more than 54 million people in Western Europe suffering from osteoarthritis, as stated by Osteoarthritis Europe. It further states that joint replacement surgery is preferred by majority of patients in the region. High incidence of osteoarthritis is boosting the osteoarthritis therapeutics market in Asia Pacific.

Analysis of Key Players

Companies are engaging in extensive R&D to stay affable. For instance, in September 2020, Sorrento Therapeutics, Inc. published positive Phase 1b trial data of resiniferatoxin (RTX) with 84-day end-point analysis for all the patients with negligible safety signals. RTX helps when patients do not respond to opioids.

Vendors are introducing medications based on symptoms. For instance, GlaxoSmithKline, in 2020 introduced Voltaren in the U.S. Novartis, in September 2021, received approval from the U.S. FDA for LNA043 as a potential first-in-class ailment modifying treatment for OA.

Horizon Pharma plc, Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Inc., Chugai Pharmaceutical Industries Ltd., Alkem Laboratories, Flexion Therapeutics, Inc., and Zimmer Biomet Holdings, Inc. are some of the key players in this market.

These companies have been profiled in the osteoarthritis drugs market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments

  • In September 2022, Alkem Laboratories received regulatory approval from the Drug Controller General of India (DCGI) for its StemOne, an off-the-shelf cell therapy product to be launched in India.
  • In August 2022, Shionogi & Co., Ltd. Initiated a licensing agreement with Grunenthal GmbH to commercialize injectable resiniferatoxin. It is meant to treat osteoarthritis of knee

Osteoarthritis Drugs Market Snapshot

Attribute Detail
Market Size in 2022 US$ 8.6 Bn
Market Forecast (Value) in 2031 US$ 17.7 Bn
Growth Rate (CAGR) 8.5%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug Class
    • Corticosteroids
    • NSAIDs & Others
    • Viscosupplementation Agents
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Horizon Pharma plc
  • Pfizer Inc.
  • Sanofi
  • Anika Therapeutics, Inc.
  • Ferring B.V.
  • Bioventus, Inc.
  • Chugai Pharmaceutical Industries Ltd.
  • Alkem Laboratories
  • Flexion Therapeutics, Inc.
  • Zimmer Biomet Holdings, Inc.
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global osteoarthritis drugs market in 2022?

It was valued at US$ 8.6 Bn in 2022

How is osteoarthritis drugs business expected to grow during the forecast period?

It is projected to grow at a CAGR of 8.5% from 2023 to 2031

What are the key factors driving the demand for osteoarthritis drugs?

Growing incidences of rheumatoid arthritis and rise in geriatric population

Which osteoarthritis drugs distribution channel held the largest share in 2022?

Hospitals accounted for the largest share in 2022

Which region dominated the global osteoarthritis drugs landscape in 2022?

North America was the dominant region in osteoarthritis drugs market in 2022

Who are the key osteoarthritis drugs manufacturers?

Horizon Pharma plc, Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Inc., Chugai Pharmaceutical Industries Ltd., Alkem Laboratories, Flexion Therapeutics, Inc., and Zimmer Biomet Holdings, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Osteoarthritis Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Drug Class, 2017–2031

            6.3.1. Corticosteroids

            6.3.2. NSAIDs & Others

            6.3.3. Viscosupplementation Agents

        6.4. Market Attractiveness Analysis, by Drug Class

    7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Route of Administration, 2017–2031

            7.3.1. Oral

            7.3.2. Parenteral

            7.3.3. Topical

        7.4. Market Attractiveness Analysis, by Route of Administration

    8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Osteoarthritis Drugs Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Drug Class, 2017–2031

            10.3.1. Corticosteroids

            10.3.2. NSAIDs & Others

            10.3.3. Viscosupplementation Agents

        10.4. Market Value Forecast, by Route of Administration, 2017–2031

            10.4.1. Oral

            10.4.2. Parenteral

            10.4.3. Topical

        10.5. Market Value Forecast, by Distribution Channel, 2017–2031

            10.5.1. Hospital Pharmacies

            10.5.2. Retail Pharmacies

            10.5.3. Online Pharmacies

        10.6. Market Value Forecast, by Country, 2017–2031

            10.6.1. U.S.

            10.6.2. Canada

        10.7. Market Attractiveness Analysis

            10.7.1. By Drug Class

            10.7.2. By Route of Administration

            10.7.3. By Distribution Channel

            10.7.4. By Country

    11. Europe Osteoarthritis Drugs Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Drug Class, 2017–2031

            11.3.1. Corticosteroids

            11.3.2. NSAIDs & Others

            11.3.3. Viscosupplementation Agents

        11.4. Market Value Forecast, by Route of Administration, 2017–2031

            11.4.1. Oral

            11.4.2. Parenteral

            11.4.3. Topical

        11.5. Market Value Forecast, by Distribution Channel, 2017–2031

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Pharmacies

        11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.6.1. Germany

            11.6.2. U.K.

            11.6.3. France

            11.6.4. Italy

            11.6.5. Spain

            11.6.6. Rest of Europe

        11.7. Market Attractiveness Analysis

            11.7.1. By Drug Class

            11.7.2. By Route of Administration

            11.7.3. By Distribution Channel

            11.7.4. By Country/Sub-region

    12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Drug Class, 2017–2031

            12.3.1. Corticosteroids

            12.3.2. NSAIDs & Others

            12.3.3. Viscosupplementation Agents

        12.4. Market Value Forecast, by Route of Administration, 2017–2031

            12.4.1. Oral

            12.4.2. Parenteral

            12.4.3. Topical

        12.5. Market Value Forecast, by Distribution Channel, 2017–2031

            12.5.1. Hospital Pharmacies

            12.5.2. Retail Pharmacies

            12.5.3. Online Pharmacies

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. China

            12.6.2. Japan

            12.6.3. India

            12.6.4. Australia & New Zealand

            12.6.5. Rest of Asia Pacific

        12.7. Market Attractiveness Analysis

            12.7.1. By Drug Class

            12.7.2. By Route of Administration

            12.7.3. By Distribution Channel

            12.7.4. By Country/Sub-region

    13. Latin America Osteoarthritis Drugs Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Drug Class, 2017–2031

            13.3.1. Corticosteroids

            13.3.2. NSAIDs & Others

            13.3.3. Viscosupplementation Agents

        13.4. Market Value Forecast, by Route of Administration, 2017–2031

            13.4.1. Oral

            13.4.2. Parenteral

            13.4.3. Topical

        13.5. Market Value Forecast, by Distribution Channel, 2017–2031

            13.5.1. Hospital Pharmacies

            13.5.2. Retail Pharmacies

            13.5.3. Online Pharmacies

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. Brazil

            13.6.2. Mexico

            13.6.3. Rest of Latin America

        13.7. Market Attractiveness Analysis

            13.7.1. By Drug Class

            13.7.2. By Route of Administration

            13.7.3. By Distribution Channel

            13.7.4. By Country/Sub-region

    14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Drug Class, 2017–2031

            14.3.1. Corticosteroids

            14.3.2. NSAIDs & Others

            14.3.3. Viscosupplementation Agents

        14.4. Market Value Forecast, by Route of Administration, 2017–2031

            14.4.1. Oral

            14.4.2. Parenteral

            14.4.3. Topical

        14.5. Market Value Forecast, by Distribution Channel, 2017–2031

            14.5.1. Hospital Pharmacies

            14.5.2. Retail Pharmacies

            14.5.3. Online Pharmacies

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. GCC Countries

            14.6.2. South Africa

            14.6.3. Rest of Middle East & Africa

        14.7. Market Attractiveness Analysis

            14.7.1. By Drug Class

            14.7.2. By Route of Administration

            14.7.3. By Distribution Channel

            14.7.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Horizon Pharma plc

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. Pfizer Inc.

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. Sanofi

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. Anika Therapeutics, Inc.

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. Ferring B.V.

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. Bioventus, Inc.

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. Chugai Pharmaceutical Industries Ltd.

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. Alkem Laboratories

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

            15.3.9. Flexion Therapeutics, Inc.

                15.3.9.1. Company Overview

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Financial Overview

                15.3.9.5. Strategic Overview

            15.3.10. Zimmer Biomet Holdings, Inc.

                15.3.10.1. Company Overview

                15.3.10.2. Product Portfolio

                15.3.10.3. SWOT Analysis

                15.3.10.4. Financial Overview

                15.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 02: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 03: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 07: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 08: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 11: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 12: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 15: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 16: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 17: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 19: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 20: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 23: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 24: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Osteoarthritis Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031

    Figure 02: Global Osteoarthritis Drugs Market Revenue (US$ Mn), by Drug Class, 2022

    Figure 03: Global Osteoarthritis Drugs Market Value Share, by Drug Class, 2022

    Figure 04: Global Osteoarthritis Drugs Market Revenue (US$ Mn), by Route of Administration, 2022

    Figure 05: Global Osteoarthritis Drugs Market Value Share, by Route of Administration, 2022

    Figure 06: Global Osteoarthritis Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022

    Figure 07: Global Osteoarthritis Drugs Market Value Share, by Distribution Channel, 2022

    Figure 08: Global Osteoarthritis Drugs Market Value Share, by Region, 2022

    Figure 09: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, 2023–2031

    Figure 10: Global Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 11: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 12: Global Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 13: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 14: Global Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 15: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 16: Global Osteoarthritis Drugs Market Value Share Analysis, by Region, 2022–2031

    Figure 17: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Region, 2023–2031

    Figure 18: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 19: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Country, 2023–2031

    Figure 20: North America Osteoarthritis Drugs Market Value Share Analysis, by Country, 2022–2031

    Figure 21: North America Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 22: North America Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 23: North America Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 24: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 25: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 26: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 27: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 28: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 29: Europe Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 30: Europe Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 31: Europe Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 32: Europe Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 33: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 34: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 35: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 36: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 37: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 38: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 39: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 40: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 41: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 42: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 43: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 44: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 45: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 46: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 47: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 48: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 49: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 50: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 51: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 52: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 53: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 54: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 55: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 56: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 57: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 58: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 59: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 60: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 61: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 62: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved